The roles of M30 and M65 in the assessment of treatment response and prognosis in patients with non-small cell lung cancer, who receive neoadjuvant treatment.

Coskun, BELKIS; Dizdar, Oguzhan; Korkmaz, Seniz; Ulukaya, Engin; EVRENSEL, TÜRKKAN

doi:10.5114/wo.2019.91539

The roles of M30 and M65 in the assessment of treatment response and prognosis in patients with non-small cell lung cancer, who receive neoadjuvant treatment.

Copy For Citation

Coskun B. N., Dizdar O. S., Korkmaz S., Ulukaya E., EVRENSEL T.

Contemporary oncology (Poznan, Poland), vol.23, no.4, pp.208-213, 2019 (Scopus)

Publication Type: Article / Article
Volume: 23 Issue: 4
Publication Date: 2019
Doi Number: 10.5114/wo.2019.91539
Journal Name: Contemporary oncology (Poznan, Poland)
Journal Indexes: Scopus
Page Numbers: pp.208-213
Bursa Uludag University Affiliated: Yes

Abstract

Aim of the study: To investigate the efficacy of evaluating prognosis and response to lung cancer treatment using M30 and M65 antigens, which are indicators of necrosis.